Shenzhen Kangtai Biological Products Co., Ltd.
Sümbol: 300601.SZ
SHZ
22.57
CNYTuruhind täna
33.0556
P/E suhe
-0.2996
PEG suhe
24.02B
MRK Cap
- 0.01%
DIV tootlus
Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) Finantsaruanded
Bilanss
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4599.59 | 1758.9 | 1458.4 | 3549.5 | ||||||||||||
balance-sheet.row.short-term-investments | 720.3 | 563.4 | 440.8 | 725.6 | ||||||||||||
balance-sheet.row.net-receivables | 11088.33 | 2819.2 | 2414.7 | 1991.2 | ||||||||||||
balance-sheet.row.inventory | 3331.33 | 772.9 | 727.8 | 1058.2 | ||||||||||||
balance-sheet.row.other-current-assets | 2231.38 | 45 | 573.9 | 741.7 | ||||||||||||
balance-sheet.row.total-current-assets | 21250.63 | 5396 | 5174.9 | 7340.7 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 22827.08 | 5756.9 | 5176.1 | 4116.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 2009.08 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2009.08 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.long-term-investments | 3309.55 | 2696.2 | 2041.3 | 99.4 | ||||||||||||
balance-sheet.row.tax-assets | 2537.58 | 630.3 | 708.3 | 558.6 | ||||||||||||
balance-sheet.row.other-non-current-assets | 7180.63 | 101.7 | 210.6 | 1297.6 | ||||||||||||
balance-sheet.row.total-non-current-assets | 37863.92 | 9689.4 | 8611.5 | 6808.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 59114.56 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.account-payables | 2706.32 | 791.2 | 434.1 | 708.2 | ||||||||||||
balance-sheet.row.short-term-debt | 1082.42 | 174.3 | 273.7 | 800.1 | ||||||||||||
balance-sheet.row.tax-payables | 80.82 | 25.9 | 173.4 | 98.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 8995.05 | 2372.2 | 2015.7 | 1938 | ||||||||||||
Deferred Revenue Non Current | 1296.77 | 328.7 | 383.1 | 349.5 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 102.52 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 3352.38 | 1757.1 | 1600.8 | 2.8 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 10251.7 | 2463.6 | 2461.2 | 2364.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-liab | 20652.76 | 5215 | 4801 | 4982.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 4467.66 | 1116.9 | 1120.5 | 687.1 | ||||||||||||
balance-sheet.row.retained-earnings | 8977.1 | 2216.7 | 1641.1 | 2435 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 18507.33 | 3117.4 | 3036 | 2417.5 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 6181.04 | 3090.6 | 3187.7 | 3627.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 38133.13 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 59114.56 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.minority-interest | -0.04 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 38133.09 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 59114.56 | - | - | - | ||||||||||||
Total Investments | 3836.89 | 3259.6 | 440.8 | 99.4 | ||||||||||||
balance-sheet.row.total-debt | 10077.46 | 2546.6 | 2289.4 | 2738.1 | ||||||||||||
balance-sheet.row.net-debt | 6198.17 | 1351 | 1271.7 | -811.4 |
Rahavoogude aruanne
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 709.91 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 35.58 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | -40.19 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 6.38 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | -411.69 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | -417.18 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 8.68 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | 0 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | -3.19 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 318.01 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 884.06 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -700.32 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0.9 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | -1042 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 831.5 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | -57.67 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -909.91 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | -289.42 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | -58.07 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | -201.98 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | -237.32 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 390.66 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -64.64 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.04 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -77.03 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 3832.6 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3909.63 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 884.06 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | -700.32 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | 183.74 | -764.7 | -888.1 | -786.8 |
Kasumiaruande rida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3167.52 | 3451.8 | 3157.4 | 3652.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 531.13 | 622.8 | 499.9 | 986.4 | ||||||||||||
income-statement-row.row.gross-profit | 2636.4 | 2829.1 | 2657.5 | 2665.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 511.11 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 84.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1132.01 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | -76.32 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.operating-expenses | 1900.36 | 2054.2 | 2020.8 | 1071.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 2431.49 | 2677 | 2520.8 | 2058.4 | ||||||||||||
income-statement-row.row.interest-income | 117.17 | 115.6 | 132.6 | 114.9 | ||||||||||||
income-statement-row.row.interest-expense | 119.01 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1132.01 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 88.6 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | -76.32 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | 88.6 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.interest-expense | 119.01 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 185.67 | 240.7 | 200.9 | 676.6 | ||||||||||||
income-statement-row.row.ebitda-caps | 947.68 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 675.06 | 774.8 | 747 | 1452.2 | ||||||||||||
income-statement-row.row.income-before-tax | 763.66 | 940.3 | -338.2 | 1439.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 53.79 | 79 | -205.5 | 175.9 | ||||||||||||
income-statement-row.row.net-income | 709.91 | 861.3 | -132.7 | 1263.4 |
Korduma kippuv küsimus
Mis on Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) koguvara?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) koguvara on 15085358535.000.
Mis on ettevõtte aastane tulu?
Aastane tulu on 1451440163.000.
Mis on ettevõtte kasumimarginaal?
Ettevõtte kasumimarginaal on 0.832.
Mis on ettevõtte vaba rahavoog?
Vaba rahavoog on 0.165.
Mis on ettevõtte puhaskasumimarginaal?
Puhaskasumimarginaal on 0.224.
Mis on ettevõtte kogutulu?
Kogutulu on 0.213.
Mis on Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) puhaskasum (puhaskasum)?
Puhaskasum (netotulu) on 861303903.000.
Kui suur on ettevõtte koguvõlg?
Koguvõlg on 2546554090.000.
Mis on tegevuskulude arv?
Tegevuskulud on 2054244031.000.
Milline on ettevõtte rahaline näitaja?
Ettevõtte raha on 876163610.000.